NCT04395053已完成1 期
Pharmacokinetic Evaluation Study of Healthy Chinese Volunteers After Oral Administration of SHR1459 Tablets in Old and New Formulation
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 28
- 试验地点
- 1
- 主要终点
- Pharmacokinetics parameter: Cmax of SHR1459
研究概览
简要总结
The primary objective of the study is to evaluate the pharmacokinetics of healthy Chinese volunteers after oral administration of SHR1459 tablets in new and old formulations.
The secondary objective of the study is to evaluate the safety after single dose of SHR1459 orally in healthy Chinese subjects.
详细描述
The PK parameters (AUC0-t, AUC0-inf, Cmax, Tmax, T1/2z, CL/F and Vz/F etc.) will be calculated to evaluate the pharmacokinetics of healthy Chinese volunteers after oral administration of SHR1459 tablets in new and old formulations.
During the study, the safety will be assessed by vital signs, physical examination, laboratory examination (hematology, blood biochemistry, urinalysis, coagulation examination), 12-lead electrocardiogram. The incidence and severity degree of adverse events and severe adverse events will be evaluated based on CTCAE 5.0.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male subjects aged 18 or above (including 18 years old) at the date of signing the informed consent;
- •Body weight ≥ 50kg, body mass index (BMI) within the range of 19 ~ 26kg /m2 (including 19 and 26 kg/m2) (BMI= weight (kg)/height 2 (m2));
- •The subjects were able to communicate well with the researchers, understand and comply with the requirements of this study, understand and sign the informed consent;
- •Consent to abstinence or take effective non-drug contraception measures during the study and for at least 3 months after the last drug administration.
排除标准
- •Anyone who has suffered from any clinical serious disease such as the circulatory system, endocrine system, nervous system, digestive system, respiratory system, urogenital system, hematology, immunology, psychiatry and metabolic abnormalities, or any other disease which can affect the study results. Researchers should focus on the following medical history: inflammatory gastroenteritis, gastroesophageal reflux, gastrointestinal or rectal bleeding, history of pancreatic injury or pancreatitis; larger history of surgery such as gastrectomy, gastrointestinal anastomosis or bowel resection;
- •Have a history of allergies to drugs, food or other substances;
- •Those who have undergone surgery within 4 weeks before the trial, or plan to undergo surgery during the study period;
- •Those who have taken any drug (including Chinese herbal medicine, vitamins, calcium tablets and other food supplements) within 14 days before the study; Those who have taken any drug that inhibits or induces liver metabolic enzymes within 30 days before the study (such as inducer-barbiturate carbamazepine, phenytoin, glucocorticoids, omeprazole; inhibitors-SSRI antidepressants, cimetidine, diltiazem, macrolides, nitroimidazoles, sedative hypnotics, vera pamil, fluoroquinolones, antihistamines);
- •Those who participated in any clinical trial and took any clinical trial drugs within 3 months before the trial;
- •Those who donated blood or suffered heavy blood loss (≥200 mL), received blood transfusions, or used blood products within 3 months before enrollment;
- •Volunteers who cannot adopt one or more non-drug contraception measures during the trial;
- •Those who have special requirements on diet and cannot follow a unified diet;
- •The subjects refused to stop any beverage or food containing methylxanthine, such as coffee, tea, cola, chocolate, etc. within 48 hours before the first dose until the end of the study; the subjects refused to discontinue any beverage or food containing grapefruit within 7 days before the first dose until the end of the study;
- •Smokers or those who smoked more than 5 cigarettes per day in the 3 months before the trial or who could not stop using any tobacco products during the trial;
- •Alcoholics or frequent drinkers within 6 months before the trial, that is, drinking more than 14 units of alcohol per week (1 unit = 360 mL beer or 45 mL of 40% spirits or 150 mL of wine), or those who receive the breath alcohol test and the results are positive, or who cannot stop using any alcoholic products during the trial;
- •Those who receive the drug abuse or urine drug screening test and the results are positive.
- •Those who regularly use sedatives, sleeping pills or other addictive drugs, have used soft drugs (such as cannabis) within 3 months before the trial or hard drugs (such as cocaine, phencyclidine, etc.) within 1 year before the trial;
- •Those with abnormal vital signs (systolic blood pressure < 90 mmHg or > 140 mmHg, diastolic blood pressure < 50 mmHg or > 90 mmHg; heart rate < 55 bpm or > 100 bpm) or the results of various clinical laboratory examination (including physical examination, electrocardiogram, chest radiograph, cardiac ultrasound, hematology, blood biochemistry, urinalysis, coagulation examination and virus serological detection) are abnormal and clinically significant based on the judgment of the clinical researchers;
- •Creatinine clearance (CLCr) < 80 mL/min, creatinine clearance should be calculated using the standard Cockcroft-Gault formula;
- •Volunteers are not able to complete the study for other reasons or other factors that are not suitable for participating in the study, as judged by the researchers.
研究组 & 干预措施
Treatment group TR
Experimental
Intervention: Drug: SHR1459, new formulation; Intervention: Drug: SHR1459, old formulation.
干预措施: SHR1459 (Drug)
Treatment group RT
Experimental
Intervention: Drug: SHR1459, old formulation; Intervention: Drug: SHR1459, new formulation.
干预措施: SHR1459 (Drug)
结局指标
主要结局
Pharmacokinetics parameter: Cmax of SHR1459
时间窗: through study completion, an average of 29 days
Peak plasma concentration （Cmax）of SHR1459
Pharmacokinetics parameter: AUC of SHR1459
时间窗: through study completion, an average of 29 days
Area under the plasma concentration versus time curve （AUC）of SHR1459
次要结局
- Pharmacokinetics parameter: Vz/F of SHR1459(through study completion, an average of 29 days)
- Pharmacokinetics parameter: T1/2z of SHR1459(through study completion, an average of 29 days)
- The number of participants with treatment-related adverse events as assessed by CTCAE v5.0(through study completion, an average of 29 days)
- Pharmacokinetics parameter: Tmax of SHR1459(through study completion, an average of 29 days)
- Pharmacokinetics parameter: CL/F of SHR1459(through study completion, an average of 29 days)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
The Safety and Tolerability of Alprostadil Liposome for Injection in Healthy Adult VolunteersLower Extremity Arterial Occlusive DiseasesNCT03669562CSPC ZhongQi Pharmaceutical Technology Co., Ltd.48
已完成
1 期
A Study of JNJ-77242113 Following Oral Administration in Healthy Chinese Adult ParticipantsHealthyNCT05703841Janssen Research & Development, LLC30
Unknown
1 期
Safety, Tolerance and Pharmacokinetics of THR-1442 in Chinese Healthy SubjectsT2DM (Type 2 Diabetes Mellitus)NCT05369078Newsoara Biopharma Co., Ltd.16
已完成
1 期
A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizumab in Healthy Adult Participants in ChinaHealthy VolunteersNCT05268068AbbVie30
已完成
1 期
Investigation of the Pharmacokinetic Properties of Biphasic Insulin Aspart 50 in Healthy Chinese SubjectsHealthyDiabetesNCT01242826Novo Nordisk A/S24